One of the things that investors need to remember with regard to stock market success is the notion of value. Ultimately, the market decides the price of the stock but there are some stocks that may stay undervalued for a variety of reasons.
Eventually, many of those stocks may go on to deliver significant gains, and hence, investors could do well to look into many of those stocks. This article provides a quick look at three stocks from the medical sector that investors could look into at this point in time.
RushNet Inc (OTCMKTS:RSHN): The first stock that makes it to this list is that of RushNet Inc. There has not been any news about the company in recent weeks but that doesn’t mean the stock is one to be ignored. In this situation, it may be a good idea for investors to consider taking a look at the announcement from the company back on February 18.
At the time, the company, along with its subsidiary companies Grandeza Healthcare and heliosDX, announced that the audit that was being carried out by the auditing firm Somerset CPAs and Advisors was progressing as planned. It was also noted that on February 18, the fifth audit was being conducted by the auditors and on top of that Somerset, personnel had also conducted a field visit to Alpharetta.
Halberd Corporation (OTCMKTS:HALB): Another healthcare stock that could be called undervalued at this point in time is Halberd Corporation. The company had come into considerable focus among investors earlier this month after it announced that it was going to move into the next stage of research and to that end, it had hired the Ravi VenkataDurvasula to be a part of its squad of consultants and experts.
Durvasula is an expert in the field of infectious diseases and he is going to be involved in Halberd Corporation’s initiatives in the same field. He will be responsible for the deployment of the patented extracorporeal disease antigen elimination process in the field of infectious diseases. It could be the next major frontier for Halberd and it may be a good time to keep an eye on the developments.
Therma Bright Inc (OTCMKTS:TBRIF) (TSXV: THRM) stock has been gaining momentum over the past week with a jump of 17%.
On March 29, the company announced at the time that it had made a submission to the United States Food and Drug Administration for the purposes of getting an Emergency Use Authorization for its AcuVid™ COVID-19 Rapid Antigen Saliva Test for Point of Care product. It was a major new announcement from the company and one that is likely to bring the stock into focus among investors as well.
The Chief Executive Officer of the company Rob Fiastpoke about the development as well. He announced that the data that was added to the application had been sourced from the clinical performance study that had been conducted in the United States and the one that had been conducted in Brazil.
Last week BioLife Sciences (OTCMKTS:BLFE) stock was in considerable focus among investors after the company announced last Friday the launch of its latest product, Copper Infused Gardening Gloves. It was a major new announcement from the company considering the fact that the Copper Infused Gardening Gloves product is one of the latest offerings from the company which belongs to its horticultural and agriculture department.
It ought to be noted in this regard that the department was launched fairly recently by the company and the latest launch is an indication that the company is taking its new business unit quite seriously. The gloves in question not only offer microbial protection and have been created with the help of the latest in the field of ergonomic research.
Immunoprecise Antibodies Ltd (NASDAQ:IPA) (TSX.V:IPA): Lastly, it is ImmunoPrecise Antibodies Ltd stock that could be on the radars of investors who are currently looking for undervalued medical stocks.
The company announced that it had signed up for a definitive share purchase agreement by way of which it is going to get control over BioStrand BV, BioKey BV, and BioClue BV through its fully owned subsidiary company ImmunoPrecise Netherlands BV. The companies that the company is taking over are a number of biotech companies and pioneers in the branches of biotechnology and bioinformatics. All the entities are based out of Belgium.
Moreover, the company had come on to the radars of investors earlier this month on March 16 when it announced its financial results for the third fiscal quarter that had ended on January 31, 2022.
ImmunoPrecise managed to bring in total revenues of $4.8 million and that reflected a rise of $0.3 million year on year. The net losses however widened to $3.8 million from $1.3 million a year ago.
